EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Radiolabelled somatostatin receptor antagonist versus agonist for peptide receptor radionuclide therapy in patients with metastatic pheochromocytoma or paraganglioma: a retrospective pilot study

Felix Schmidt, Sofia-Maria Lider, Lisa McDougall, Christopher Eigler, Peter Bernhardt, Abdulrafee Mushaweh, Andreas Bauman, Melpomeni Fani, Emanuel Christ, Damian Wild

European Journal of Nuclear Medicine and Molecular Imaging · 2026-11 · 53 (13) · 8262-8271

DOI: 10.1007/s00259-026-08122-8 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 12.08.2026. Verfasst von Felix Schmidt und 9 weiteren Autor:innen. Beteiligte Einrichtung: Clinic for Radiology and Nuclear Medicine, University Hospital Basel, Petersgraben 4, Basel, CH-4031, Switzerland. Hauptthemen laut MEDLINE: Paraganglioma, Receptors, Somatostatin, Pheochromocytoma, Octreotide. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Basel.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Metastatic pheochromocytomas and paragangliomas (mPPGLs) are rare neuroendocrine tumours with limited therapeutic options. Peptide receptor radionuclide therapy (PRRT) using somatostatin receptor (SSTR) antagonists (e.g. [ 177 Lu]Lu-DOTA-JR11) may achieve higher tumour and organ absorbed doses compared with standard SSTR agonist therapy (e.g. [ 177 Lu]Lu-DOTA-TOC). This study aimed to perform an intra-patient comparison of tumour and organ dosimetry between [ 177 Lu]Lu-DOTA-TOC and [ 177 Lu]Lu-DOTA-JR11 in patients with mPPGLs refractory to conventional therapies. Secondary endpoints included safety and exploratory clinical efficacy of [ 177 Lu]Lu-DOTA-JR11.

Methods

In this retrospective pilot study, 6 patients with mPPGLs received 1–2 cycles of [ 177 Lu]Lu-DOTA-TOC (~ 7.4 GBq/cycle), followed by 1–2 cycles of [ 177 Lu]Lu-DOTA-JR11 (2 GBq/m 2 × body surface area) at an interval of 10–12 weeks. Endpoints included estimation of tumour and organ absorbed doses, assessment of safety according to the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 and symptoms, and evaluation of progression-free survival (PFS) before and after [ 177 Lu]Lu-DOTA-JR11 therapy.

Results

Intra-patient comparison showed that the median tumour absorbed dose per cycle was 1.3-fold higher (range 0.9–3.5) with [ 177 Lu]Lu-DOTA-JR11 than with [ 177 Lu]Lu-DOTA-TOC. This was associated with longer PFS after [ 177 Lu]Lu-DOTA-JR11 (12.5 months; range 6 – >20) versus PFS before inclusion (3.5 months; range 1–9). The most severe adverse event was grade 3 lymphopenia in one patient. No thrombocytopenia, neutropenia, creatinine elevation or alanine aminotransferase elevation was observed. Conclusion [ 177 Lu]Lu-DOTA-JR11 resulted in higher tumour absorbed doses than [ 177 Lu]Lu-DOTA-TOC and was associated with longer post-treatment PFS than PFS before inclusion in this small cohort. Treatment was well tolerated, supporting further prospective evaluation in patients with mPPGLs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ParagangliomaReceptors, SomatostatinPheochromocytomaOctreotideAdrenal Gland NeoplasmsHumansPilot ProjectsRetrospective StudiesFemaleMaleMiddle AgedAgedAdultLutetiumNeoplasm MetastasisTreatment OutcomeOrganometallic Compounds

Stichwörter der Autor:innen

DOTA-JR11Malignant pheochromocytoma and paragangliomaRadioligand therapySomatostatin receptor

Substanzen

Receptors, SomatostatinOctreotideLutetiumOrganometallic Compounds

Autor:innen und Institutionen

  • Clinic for Radiology and Nuclear Medicine, University Hospital Basel, Petersgraben 4, Basel, CH-4031, Switzerland.
  • "Ana Aslan" National Institute of Geriatrics and Gerontology, Bucharest, Romania.
  • Department of Medical Radiation Sciences, Institution of Clinical Science, University of Gothenburg, Gothenburg, Sweden.
  • ENETS Center of Excellence for Neuroendocrine and Endocrine Tumours, University Hospital Basel, Basel, Switzerland.
  • Department of Endocrinology, University Hospital Basel, Basel, Switzerland.
  • Clinic for Radiology and Nuclear Medicine, University Hospital Basel, Petersgraben 4, Basel, CH-4031, Switzerland. damian.wild@usb.ch.

Förderung

  • University of Basel

Zitieren

APA

Schmidt, F., Lider, S. M., McDougall, L., Eigler, C., Bernhardt, P., Mushaweh, A., Bauman, A., Fani, M., Christ, E., & Wild, D. (2026). Radiolabelled somatostatin receptor antagonist versus agonist for peptide receptor radionuclide therapy in patients with metastatic pheochromocytoma or paraganglioma: a retrospective pilot study. European Journal of Nuclear Medicine and Molecular Imaging, 53(13), 8262-8271. https://doi.org/10.1007/s00259-026-08122-8

Vancouver

Schmidt F, Lider SM, McDougall L, Eigler C, Bernhardt P, Mushaweh A, et al. Radiolabelled somatostatin receptor antagonist versus agonist for peptide receptor radionuclide therapy in patients with metastatic pheochromocytoma or paraganglioma: a retrospective pilot study. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(13):8262-8271. doi:10.1007/s00259-026-08122-8

BibTeX
@article{Schmidt2026,
  author = {Schmidt, Felix and Lider, Sofia-Maria and McDougall, Lisa and Eigler, Christopher and Bernhardt, Peter and Mushaweh, Abdulrafee and Bauman, Andreas and Fani, Melpomeni and Christ, Emanuel and Wild, Damian},
  title = {Radiolabelled somatostatin receptor antagonist versus agonist for peptide receptor radionuclide therapy in patients with metastatic pheochromocytoma or paraganglioma: a retrospective pilot study},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  volume = {53},
  number = {13},
  pages = {8262--8271},
  doi = {10.1007/s00259-026-08122-8}
}
Kostenlos starten →